Ianalumab Biosimilar - Research Grade

Human

TNFRSF13C

>1mg/ml

IgG1 - kappa

CHO Cells

https://www.imgt.org/mAb-DB/

ICH3002

Q96RJ3

115650

Blue ice

This product is an unconjugated, non-therapeutic recombinant analog of ianalumab, a fully human IgG1-kappa antibody directed against human BAFF-R (B-cell activating factor receptor, TNFRSF13C). It is supplied for research use only (RUO) and is not the clinical drug; it is not intended for human or veterinary use. Built around the BAFF-R target, the analog is useful for functional studies of the BAFF/BAFF-R axis in B-cell survival and for benchmarking receptor-blockade versus ligand-neutralisation strategies. Typical research applications include use as a positive binding control, an isotype-matched reagent in receptor-occupancy and competition assays, a tool for interrogating BAFF-R signalling in cultured primary B cells or cell lines, and a reference antibody in ADCC and Fc-engineering/ADC-development workflows. It is offered at research grade with low endotoxin (<1 EU/mg; ultra-low <0.5 EU/mg options) and available in bulk milligram-to-gram quantities to support assay development, in-vitro standards, and preclinical characterisation. Because it is a biosimilar built to the originator target rather than the marketed product, it should be validated in the user's own system before use. TNFRSF13C encodes BAFF-R (B-cell activating factor receptor, also called BR3 or CD268), a member of the TNF receptor superfamily expressed predominantly on the surface of mature and transitional B lymphocytes. It is the principal receptor for BAFF (B-cell activating factor, also known as BLyS/TNFSF13B), and their engagement delivers a dominant pro-survival signal, chiefly through activation of the non-canonical NF-kB pathway, driving peripheral B-cell maturation, homeostasis, and persistence. BAFF is present in both soluble and membrane-bound forms, and BAFF-R binds it with high selectivity relative to the related receptors TACI and BCMA. Dysregulated BAFF/BAFF-R signalling supports autoreactive B-cell survival and is implicated in autoimmune conditions such as Sjogren's disease, systemic lupus erythematosus, and rheumatoid arthritis, making the receptor an attractive target for B-cell-directed therapeutic and research strategies.

B-cell-activating factor receptor, BAFF receptor, BAFF-R, BLyS receptor 3, Tumor necrosis factor receptor superfamily member 13C, BR3

This monoclonal antibody was purified using Protein A

Sterile, preservative-free, solution in PBS. BSA and Azide free.

This biosimilar is stable when stored at 2-8°C. For longer term storage (> 3 months) it is recommended to store this antibody at -20°C or -70°C.

Functional Assays

This biosimilar is for research use only (RUO): it is not for diagnostic or therapeutic procedures and cannot be purchased by patients.

Products are for research use only. Not for use in diagnostic or therapeutic procedures.

3-4 weeks

Ianalumab (anti-TNFRSF13C) Biosimilar

Q: Is the Ianalumab biosimilar available in bulk or gram quantities?

A: Yes — the Ianalumab biosimilar is manufactured in scalable milligram to gram quantities to support high-throughput and heavy-usage laboratories.

Q: Is this research-grade Ianalumab suitable for in vivo studies?

A: Yes, it is a low-endotoxin, in vivo-ready formulation intended for preclinical and in vivo research use only (RUO).

Q: What does the Ianalumab biosimilar target?

A: It is an unconjugated, non-therapeutic analog of Ianalumab that binds TNFRSF13C.